Data Sheet 1 from a study by Xiaoling Tian, last updated in April 2026, explores the role of adenosine deaminase (ADA) in esophageal cancer. The dataset likely contains results from a multi-level analysis including Mendelian randomization, serum validation, transcriptomic analysis, and single-cell RNA sequencing. Findings suggest ADA as a potential risk factor and identify candidate compounds for intervention.
Use Cases
- Validate genetic associations for esophageal cancer based on Mendelian randomization results mentioned in the description.
- Analyze co-expression network enrichment based on pathways like 'proteasome' and 'protein folding' described in the study.
- Investigate single-cell expression patterns based on the finding of high ADA expression in plasma and plasmacytoid dendritic cells.
- Screen for potential drug compounds based on the identified lead molecules, catechin and flavoxanthin.
Strengths
- Dataset is derived from a multi-method study including Mendelian randomization, serum validation, and single-cell RNA sequencing.
- Results include specific statistical measures, such as an odds ratio (OR) of 1.23 for ADA's association with esophageal cancer.
- Published under a permissive CC-BY-4.0 license, facilitating reuse.
Limitations
- Row count is unknown, which may limit suitability assessment.
- Column-level documentation is absent; field semantics must be inferred after download.
- The dataset is very small at 9.5 KB, indicating limited scope or summary-level data.
Provenance
- Source
- figshare, author Xiaoling Tian
- Collection Method
- Multi-level integrative analysis including Mendelian randomization, serum validation, transcriptomic analysis, co-expression network enrichment, single-cell RNA sequencing, reverse network pharmacology, and molecular docking.
- Time Range
- null
- Freshness
- Last updated 2026-04-23 04:21:40; freshness should be verified.
- Geography
- null